Newsfiscal.ai
BioLineRx and Hemispherian Present Preclinical Data on GLIX1 Synergy with PARP Inhibitors at ESMO 2026
· Published
Article summary
BioLineRx and its joint venture partner Hemispherian AS presented preclinical data at the ESMO 2026 congress demonstrating that GLIX1 acts synergistically with PARP inhibitors in HR-proficient ovarian cancer models.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…